Have a personal or library account? Click to login
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals Cover

Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals

Radiology and Oncology
Volume 52 (2018): Issue 3 (September 2018)
By: Borut Kobal,  Marco Noventa,  Branko Cvjeticanin,  Matija Barbic,  Leon Meglic,  Marusa Herzog,  Giulia Bordi,  Amerigo Vitagliano,  Carlo Saccardi and  Erik Skof  
Open Access
|Sep 2018

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30. 10.3322/caac.21387
    Open DOISearch in Google ScholarBack to article
  2. Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol 2016; 142: 597-607. 10.1016/j.ygyno.2016.06.013
    Open DOISearch in Google ScholarBack to article
  3. Kumar L, Pramanik R, Kumar S, Bhatla N, Malik S. Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging. Best Pract Res Clin Obstet Gynaecol 2015; 29: 790-801. 10.1016/j.bpobgyn.2015.02.008
    Open DOISearch in Google ScholarBack to article
  4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe ďInvestigateurs Nationaux Pour les Etudes des Cancers de ľOvaire (GINECO). Cancer 2009 15; 115: 1234-44. 10.1002/cncr.24149
    Open DOISearch in Google ScholarBack to article
  5. Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 2017; 144: 474-9. 10.1016/j.ygyno.2016.12.017
    Open DOISearch in Google ScholarBack to article
  6. Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY, et al. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol 2015; 139: 394-400. 10.1016/j.ygyno.2015.08.026
    Open DOISearch in Google ScholarBack to article
  7. Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 2015; 137: 553-8. 10.1016/j.ygyno.2015.03.049
    Open DOISearch in Google ScholarBack to article
  8. Melamed A, Hinchcliff EM, Clemmer JT, Bregar AJ, Uppal S, Bostock I, et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol Oncol 2016; 143: 236-40. 10.1016/j.ygyno.2016.09.002
    Open DOISearch in Google ScholarBack to article
  9. May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B, et al. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. Int J Gynecol Cancer 2017; 27: 668-74. 10.1097/IGC.0000000000000946
    Open DOISearch in Google ScholarBack to article
  10. Mueller JJ, Zhou QC, Iasonos A, O’Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016; 140: 436-42. 10.1016/j.ygyno.2016.01.008
    Open DOISearch in Google ScholarBack to article
  11. Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014; 134: 462-7. 10.1016/j.ygyno.2014.07.004
    Open DOISearch in Google ScholarBack to article
  12. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-57. 10.1016/S0140-6736(14)62223-6
    Open DOISearch in Google ScholarBack to article
  13. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53. 10.1056/NEJMoa0908806
    Open DOISearch in Google ScholarBack to article
  14. Mahner S, Trillsch F, Chi D, Harter P, Pfisterer J, Hilpert F, et al. Neoadjuvant chemotherapy in ovarian cancer revisited. Ann Oncol 2016; 27 (Suppl 1): i30-2. 10.1093/annonc/mdw092
    Open DOISearch in Google ScholarBack to article
  15. Cornelis S, Van Calster B, Amant F, Leunen K, van der Zee AG, Vergote I. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology. Int J Gynecol Cancer 2012; 22: 407-16. 10.1097/IGC.0b013e31823ea1d8
    Open DOISearch in Google ScholarBack to article
  16. Dewdney SB, Rimel BJ, Reinhart AJ, Kizer NT, Brooks RA, Massad LS, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010; 119: 18-21. 10.1016/j.ygyno.2010.06.021
    Open DOISearch in Google ScholarBack to article
  17. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003; 88: 9-16. 10.1006/gyno.2002.6849
    Open DOISearch in Google ScholarBack to article
  18. Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, et al. European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol 2013; 131: 437-44. 10.1016/j.ygyno.2013.08.014
    Open DOISearch in Google ScholarBack to article
  19. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-96. 10.1097/SLA.0b013e3181b13ca2
    Open DOISearch in Google ScholarBack to article
  20. Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 2017; 28: 711-7. 10.1093/annonc/mdx011
    Open DOISearch in Google ScholarBack to article
  21. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013; 130: 493-8. 10.1016/j.ygyno.2013.05.040
    Open DOISearch in Google ScholarBack to article
  22. Brand AH. Ovarian cancer debulking surgery: a survey of practice in Australia and New Zealand. Int J Gynecol Cancer 2011; 21: 30-5. 10.1097/IGC.0b013e318205fb4f
    Open DOISearch in Google ScholarBack to article
  23. Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol 2016; 142: 211-6. 10.1016/j.ygyno.2016.05.025
    Open DOISearch in Google ScholarBack to article
  24. Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, et al. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol 2017; 3: 76-82. 10.1001/jamaoncol.2016.4411
    Open DOISearch in Google ScholarBack to article
  25. Petrillo M, Ferrandina G, Fagotti A, Vizzielli G, Margariti PA, Pedone AL, et al. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 2013; 20: 3955-60. 10.1245/s10434-013-3091-6
    Open DOISearch in Google ScholarBack to article
  26. da Costa AA, Valadares CV, Baiocchi G, Mantoan H, Saito A, Sanches S, et al. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Ann Surg Oncol 2015; 22 (Suppl 3): S971-8. 10.1245/s10434-015-4623-z
    Open DOISearch in Google ScholarBack to article
  27. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011; 12: 1169-74. 10.1016/S1470-2045(11)70123-1
    Open DOISearch in Google ScholarBack to article
  28. Bian C, Yao K, Li L, Yi T, Zhao X. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet 2016; 293: 63-8. 10.1007/s00404-015-3813-z
    Open DOISearch in Google ScholarBack to article
  29. Lim MC, Yoo HJ, Song YJ, Seo SS, Kang S, Kim SH, et al. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. J Gynecol Oncol 2017; 28: e48. 10.3802/jgo.2017.28.e48
    Open DOISearch in Google ScholarBack to article
  30. Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol 2015; 126: 491-7. 10.1097/AOG.0000000000000981
    Open DOISearch in Google ScholarBack to article
  31. Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep 2014; 16: 389. 10.1007/s11912-014-0389-x
    Open DOISearch in Google ScholarBack to article
  32. Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, et al. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol 2017; 144: 57-60. 10.1016/j.ygyno.2016.11.001
    Open DOISearch in Google ScholarBack to article
  33. Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecol Oncol 2017; 144: 266-73. 10.1016/j.ygyno.2016.11.021
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/raon-2018-0030 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 307 - 319
Submitted on: Mar 28, 2018
|
Accepted on: Jul 23, 2018
|
Published on: Sep 11, 2018
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
epithelial ovarian cancer,
advanced stage,
primary debulking surgery,
interval debulking surgery,
neoadjuvant chemotherapy,
adjuvant chemotherapy,
overall survival,
progression free survival
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2018 Borut Kobal, Marco Noventa, Branko Cvjeticanin, Matija Barbic, Leon Meglic, Marusa Herzog, Giulia Bordi, Amerigo Vitagliano, Carlo Saccardi, Erik Skof, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 52 (2018): Issue 3 (September 2018)Next article